Yong Zha1, Ping Gan2, Qin Liu2, Qian Yao2. 1. Department of Abdominal Surgery, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, Yunnan, PR China. Electronic address: zhayong888@sina.com. 2. Department of Abdominal Surgery, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital), Kunming, Yunnan, PR China.
Abstract
BACKGROUND AND AIMS: The present study analyzed the relationship between TP53 codon 72 polymorphisms and the clinical outcome of advanced gastric cancer patients receiving capecitabine plus paclitaxel chemotherapy. METHODS: Three hundred patients with advanced gastric cancer treated with paclitaxel and capecitabine combination chemotherapy were enrolled in the present study. Genomic DNA was extracted from peripheral blood leukocytes and determined using allele specific polymerase chain reaction (AS-PCR). Correlation between TP53 codon 72 polymorphisms and treatment response, gastric cancer survival was analyzed. RESULTS: The Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to capecitabine plus paclitaxel chemotherapy in patients with gastric cancer when compared to the Arg/Arg genotype (30.6 vs. 63.2%, p value 0.000). Multivariate survival analysis also showed that the progression free survival (PFS) and overall survival (OS) for patients with Pro/Pro genotypes of TP53 codon 72 were worse than for those with the Arg/Arg genotype (hazard ratio [HR] = 2.177, p = 0.009; HR = 2.145, p = 0.038, respectively). CONCLUSIONS: TP53 codon 72 polymorphisms was effective in predicting the response to chemotherapy and correlate with PFS and OS in patients with advanced gastric cancer treated with paclitaxel and capecitabine chemotherapy.
BACKGROUND AND AIMS: The present study analyzed the relationship between TP53 codon 72 polymorphisms and the clinical outcome of advanced gastric cancerpatients receiving capecitabine plus paclitaxel chemotherapy. METHODS: Three hundred patients with advanced gastric cancer treated with paclitaxel and capecitabine combination chemotherapy were enrolled in the present study. Genomic DNA was extracted from peripheral blood leukocytes and determined using allele specific polymerase chain reaction (AS-PCR). Correlation between TP53 codon 72 polymorphisms and treatment response, gastric cancer survival was analyzed. RESULTS: The Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to capecitabine plus paclitaxel chemotherapy in patients with gastric cancer when compared to the Arg/Arg genotype (30.6 vs. 63.2%, p value 0.000). Multivariate survival analysis also showed that the progression free survival (PFS) and overall survival (OS) for patients with Pro/Pro genotypes of TP53 codon 72 were worse than for those with the Arg/Arg genotype (hazard ratio [HR] = 2.177, p = 0.009; HR = 2.145, p = 0.038, respectively). CONCLUSIONS:TP53 codon 72 polymorphisms was effective in predicting the response to chemotherapy and correlate with PFS and OS in patients with advanced gastric cancer treated with paclitaxel and capecitabine chemotherapy.
Authors: Laura C Funk; Jun Wan; Sean D Ryan; Charanjeet Kaur; Ruth Sullivan; Avtar Roopra; Beth A Weaver Journal: Mol Cancer Res Date: 2020-09-18 Impact factor: 6.333
Authors: Lei Zhang; Yi Wang; Zhiqiang Qin; Ran Li; Rong Cong; Chengjian Ji; Xianghu Meng; Yamin Wang; Jiadong Xia; Ninghong Song Journal: J Cancer Date: 2018-09-08 Impact factor: 4.207
Authors: Raid A Jastania; Muhammad Saeed; Hisham Al-Khalidi; Khalid AlQuthami; Tahani H Nageeti; Faisal A Al-Allaf; Kristoffer Valerie; Mohiuddin M Taher Journal: Int Med Case Rep J Date: 2020-04-21